Merck restructuring involves creating a standalone cancer unit and a second business for other drugs, impacting Keytruda’s future.
Browsing: Market & Financials
Market trends, financial performance, quarterly results, and investment insights from global pharma and biotech companies.
Lilly earnings guidance indicates 2025 sales of Zepbound and Mounjaro exceeding $36 billion, surpassing Wall Street expectations.
Johnson & Johnson sales are expected to reach $100B by 2025, driven by cancer and immune drugs, despite patent challenges.
Insmed lung drug sales surpass expectations in Q1 2025, while J&J secures a US pricing deal.
Biopharma CEO optimism varies globally, with US executives showing less confidence. Survey reveals differences in outlook.
Drug price deals with Trump involve 9 drugmakers, impacting tariffs and benefits. Analysts see limited financial effect.
Aktis IPO Filing comes as the biotech sector shows signs of recovery, raising hopes for a rebound in IPO activity in 2025.
Moderna H5 influenza vaccine receives undisclosed funding, reviving efforts after losing government support earlier this year.
Insmed drug failure in a study leads to a valuation drop of nearly 20%, affecting its $40 billion market cap.
Orum $100M financing supports its strategic shift towards developing a blood cancer treatment, enhancing its innovative pipeline.